Evidence map›Paper›PMID 36374927›Full record

ArticlePloS one2022

Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.

Mona A Abu El-Makarem, Mariana F Kamel, Ahmed A Mohamed, Hisham A Ali, Mahmoud R Mohamed, Alaa El-Deen M Mohamed, Ahmed M El-Said, Mahmoud G Ameen, Alshymaa A Hassnine, Hatem A Hassan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Serum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mona A Abu El-MakaremDepartment of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.ORCID 0000-0001-9202-4373
Mariana F KamelDepartment of Pathology, School of Medicine, Minia University, Minia, Egypt.
Ahmed A MohamedDepartment of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.
Hisham A AliDepartment of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.
Mahmoud R MohamedDepartment of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.
Alaa El-Deen M MohamedDepartment of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.
Ahmed M El-SaidDepartment of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.
Mahmoud G AmeenDepartment of Pathology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt.
Alshymaa A HassnineDepartment of Tropical Medicine and Gastroenterology, School of Medicine, Minia University, Minia, Egypt.ORCID 0000-0003-1352-0948
Hatem A HassanDepartment of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.
Minia University · EGAssiut University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsSo far, few clinical trials are available concerning the role of growth hormone receptor (GHR)/signal transducer and activator of transcription 5 (STAT5)/insulin like growth factor-1 (IGF-1) axis in hepatocarcinogenesis. The aim of this study was to evaluate the hepatic expression of GHR/STAT5/IGF-1 signaling pathway in hepatocellular carcinoma (HCC) patients and to correlate the results with the clinico-pathological features and disease outcome. The interaction between this signaling pathway and some inducers of epithelial-mesenchymal transition (EMT), namely Snail-1 and type 2 transforming growth factor-beta receptor (TGFBR2) was studied too. MATERIAL AND

methodsA total of 40 patients with HCV-associated HCC were included in this study. They were compared to 40 patients with HCV-related cirrhosis without HCC, and 20 healthy controls. The hepatic expression of GHR, STAT5, IGF-1, Snail-1 and TGFBR2 proteins were assessed by immunohistochemistry.

resultsCompared with cirrhotic patients without HCC and healthy controls, cirrhotic patients with HCC had significantly lower hepatic expression of GHR, STAT5, and IGF-1proteins. They also displayed significantly lower hepatic expression of TGFBR2, but higher expression of Snail-1 versus the non-HCC cirrhotic patients and controls. Serum levels of alpha-fetoprotein (AFP) showed significant negative correlations with hepatic expression of GHR (r = -0.31; p = 0.029) and STAT5 (r = -0.29; p = 0.04). Hepatic expression of Snail-1 also showed negative correlations with GHR, STAT5, and IGF-1 expression (r = -0.55, p = 0.02; r = -0.472, p = 0.035, and r = -0.51, p = 0.009, respectively), whereas, hepatic expression of TGFBR2 was correlated positively with the expression of all these proteins (r = 0.47, p = 0.034; 0.49, p = 0.023, and r = 0.57, p<0.001, respectively). Moreover, we reported that decreased expression of GHR was significantly associated with serum AFP level>100 ng/ml (p = 0.048), increased tumor size (p = 0.02), vascular invasion (p = 0.002), and advanced pathological stage (p = 0.01). Similar significant associations were found between down-regulation of STAT5 expression and AFP level > 100 ng/ml (p = 0.006), vascular invasion (p = 0.009), and advanced tumor stage (p = 0.007). Also, attenuated expression of IGF-1 showed a significant association with vascular invasion (p < 0.001). Intriguingly, we detected that lower expression of GHR, STAT5 and IGF-1 were considered independent predictors for worse outcome in HCC.

conclusionDecreased expression of GHR/STAT5/IGF-1 signaling pathway may have a role in development, aggressiveness, and worse outcome of HCV-associated HCC irrespective of the liver functional status. Snail-1 and TGFBR2 as inducers of EMT may be key players. However, large prospective multicenter studies are needed to validate these results.

Indexed as

Carcinoma, HepatocellularHepatitis CLiver Neoplasmsalpha-FetoproteinsDown-RegulationHumansInsulin-Like Growth Factor ILiver CirrhosisProspective StudiesReceptors, SomatotropinReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IISignal TransductionSTAT5 Transcription FactorTransforming Growth Factorsalpha-FetoproteinsInsulin-Like Growth Factor IReceptors, SomatotropinReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IISTAT5 Transcription FactorTransforming Growth Factors

Identifiers

PMID36374927
PMCPMC9662744
OpenAlexW4308964424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.